AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Nicostatin, rosuvastatin, and ezetimibe are three new lipid-lowering drugs that are likely to be approved this year, Dr. Donald B. Hunninghake predicted at a conference sponsored by the American College of Cardiology.
Nicostatin (Advicor) received Food and Drug Administration approval in December. Rosuvastatin and ezetimibe are expected to win FDA approval without difficulty later this year, said Dr. Hunninghake of the University of Minnesota, Minneapolis.
All three drugs have excellent safety profiles. Each offers notable advantages over existing therapies in terms of efficacy and/or convenience, he said.
Nicostatin combines extended-release niacin with lovastatin. The combined effects of the two drugs on LDL, HDL, and triglycerides are greater ...